Male Hypogonadism - Pipeline Review, H2 2016

Date: July 27, 2016
Pages: 106
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MAE8068302AEN
Leaflet:

Download PDF Leaflet

Male Hypogonadism - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Male Hypogonadism - Pipeline Review, H2 2016’, provides an overview of the Male Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
  • The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects
  • The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Male Hypogonadism
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism Overview
Therapeutics Development
Pipeline Products for Male Hypogonadism - Overview
Pipeline Products for Male Hypogonadism - Comparative Analysis
Male Hypogonadism - Therapeutics under Development by Companies
Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes
Male Hypogonadism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Male Hypogonadism - Products under Development by Companies
Male Hypogonadism - Products under Investigation by Universities/Institutes
Male Hypogonadism - Companies Involved in Therapeutics Development
Antares Pharma, Inc.
Clarus Therapeutics, Inc.
Endo Pharmaceuticals Inc.
EndoCeutics, Inc.
Ferring International Center S.A.
Forendo Pharma Limited
Lipocine Inc.
M et P Pharma AG
Merck & Co., Inc.
Mereo Biopharma Group Plc
Millennium Pharmaceuticals Inc
Pantarhei Bioscience BV
Repros Therapeutics Inc.
Variant Pharmaceuticals, Inc.
Male Hypogonadism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BGS-649 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fispemifene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSS-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-448 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone enanthate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism - Dormant Projects
Male Hypogonadism - Discontinued Products
Male Hypogonadism - Product Development Milestones
Featured News & Press Releases
Jul 06, 2016: Aytu BioScience Provides Update on Natesto Product Launch
Jun 30, 2016: Aytu BioScience to Host Conference Call to Detail Company’s Natesto U.S. Launch Plans
Jun 28, 2016: Aytu BioScience Announces Presentation of Clinical Data Highlighting Efficacy of Natesto (Testosterone) Nasal Gel in Men with Seasonal Allergies
Jun 17, 2016: Acerus Announces NATESTO Scientific Abstract Presentation at the 71st Annual Canadian Urological Association Meeting
Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Jun 01, 2016: Antares Pharma Announces Phase 3 trail Update on QuickShot Testosterone Clinical Program
May 18, 2016: Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto
Apr 19, 2016: Transdermal Delivery Solutions Announces Regulatory Approval of Clinical Trials Commencement of Testagen Topical Testosterone HypoSpray
Mar 28, 2016: Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism
Mar 16, 2016: Antares Pharma Announces Completion of the 52 Week QuickShot Phase 3 Study in Testosterone Deficient Men
Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Male Hypogonadism, H2 2016
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Male Hypogonadism - Pipeline by Antares Pharma, Inc., H2 2016
Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H2 2016
Male Hypogonadism - Pipeline by Endo Pharmaceuticals Inc., H2 2016
Male Hypogonadism - Pipeline by EndoCeutics, Inc., H2 2016
Male Hypogonadism - Pipeline by Ferring International Center S.A., H2 2016
Male Hypogonadism - Pipeline by Forendo Pharma Limited, H2 2016
Male Hypogonadism - Pipeline by Lipocine Inc., H2 2016
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2016
Male Hypogonadism - Pipeline by Merck & Co., Inc., H2 2016
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2016
Male Hypogonadism - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H2 2016
Male Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2016
Male Hypogonadism - Pipeline by Variant Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Male Hypogonadism - Dormant Projects, H2 2016
Male Hypogonadism - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Male Hypogonadism, H2 2016
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Antares Pharma, Inc.
Clarus Therapeutics, Inc.
Endo Pharmaceuticals Inc.
EndoCeutics, Inc.
Ferring International Center S.A.
Forendo Pharma Limited
Lipocine Inc.
M et P Pharma AG
Merck & Co., Inc.
Mereo Biopharma Group Plc
Millennium Pharmaceuticals Inc
Pantarhei Bioscience BV
Repros Therapeutics Inc.
Variant Pharmaceuticals, Inc.
Skip to top


Male Infertility - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 44 pages
Male Infertility - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 46 pages

Ask Your Question

Male Hypogonadism - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: